GeoVax Labs (GOVX) Total Non-Current Liabilities (2020 - 2022)
GeoVax Labs (GOVX) posted quarterly Total Non-Current Liabilities of $2.7 million for Q4 2022, down 49.44% year-over-year from $5.4 million in Q4 2021, and down 42.63% quarter-over-quarter from $4.8 million in Q3 2022.
GeoVax Labs (GOVX) Total Non-Current Liabilities (2020 - 2022) Analysis & Trends
GeoVax Labs (GOVX) has reported Total Non-Current Liabilities for 3 consecutive years, with $2.7 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Total Non-Current Liabilities fell 49.44% year-over-year to $2.7 million; the TTM figure through Dec 2022 stood at $2.7 million (down 49.44% YoY), while the FY2022 annual figure was $2.7 million, down 49.44% from the prior year.
- Total Non-Current Liabilities slipped to $2.7 million in Q4 2022 per GOVX's latest filing, from $4.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.4 million in Q4 2021 and bottomed at $825047.0 in Q4 2020.
- Historically, Total Non-Current Liabilities has averaged $3.4 million across 3 years, with a median of $3.4 million in 2022.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 558.79% — and 2022, when it plunged 49.44%.
- GeoVax Labs' Total Non-Current Liabilities stood at $825047.0 in 2020, then surged by 558.79% to $5.4 million in 2021, then slumped by 49.44% to $2.7 million in 2022.
- Business Quant data shows GOVX's Total Non-Current Liabilities at $2.7 million in Q4 2022, $4.8 million in Q3 2022, and $3.4 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | GeoVax Labs | 2.88 Mn | -267,341.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 4.79 Mn |
| Jun 30, 2022 | 3.37 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Dec 31, 2021 | 5.44 Mn |
| Dec 31, 2020 | 825,047.00 |